Translational Cardiac Stem Cell Program ( TCSCP ) 2017
Developing Revolutionary Treatments for Multiple Diseases Dr. Yerem founded the TCSCP in 2003 to develop revolutionary treatments for life threatening diseases by taking stem cell therapies from the lab to the bedside. With groundbreaking discoveries, the TCSCP has developed novel promising therapies for multiple conditions including cardiovascular diseases, cancer, neurodegenerative diseases, diabetes, muscular dystrophies and even hair loss and aging. The TCSCP has: Published more than 100 peer reviewed articles in prestigious medical journals and identified new treatments destined for clinical application Discovered new stem cell proteins that can be developed into very promising new drugs to treat heart disease and stroke Developed a new proprietary disruptive technology that can be used to discover completely new drugs, which can be developed into novel clinical therapies for millions of patients with unmet medical needs globally 2
Fighting Some of the Most Deadly Diseases: Cardiovascular Disease Cardiovascular disease, listed as the underlying cause of death, accounts for nearly 801,000 deaths in the U.S. That s about 1 of every 3 deaths in the U.S About 2,200 Americans die of cardiovascular disease each day, an average of 1 death every 40 seconds Heart disease accounts for 1 in 7 deaths in the U.S. About 790,000 people in the US have heart attacks each year Of those, about 114,000 will die 3
Fighting Some of the Most Deadly Diseases: Cancer Cancer is among the leading causes of death worldwide. In 2012, there were 14 million new cases and 8.2 million cancerrelated deaths worldwide For many cancers, such as brain, lung, and pancreas, just to name a few, there are no effective therapies. The number of cancer deaths is over 170 per 100,000 men and women per year Approximately 40% of men and women will be diagnosed with cancer at some point during their lifetimes The number of new cancer cases will rise to 22 million within the next two decades 4
Fighting Some of the Most Deadly Diseases: Neurodegenerative Diseases Five million Americans suffer from Alzheimer's disease; one million from Parkinson's; 400,000 from multiple sclerosis (MS); 30,000 from amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and 30,000 from Huntington's disease There are no effective therapies for these diseases If left unchecked 30 years from now, more than 12 million Americans will suffer from neurodegenerative diseases Neurodegenerative diseases occur when nervous system cells (neurons) begin to deteriorate In some cases, patients lose the ability to walk independently, think clearly, or generally function in the world Ultimately, many of these diseases are fatal 5
TCSCP Director s Bios Name Dr. Yerem Yeghiazarians, MD. Professor of Medicine UCSF Bio Dr. Yerem, a leader in the medical industry, joined UCSF in 2003. He is an interventional cardiologist with expertise in managing patients with coronary artery disease, acute coronary syndromes, valvular heart disease, cardiomyopathies, patent foramen ovale, and peripheral arterial diseases. Currently he is the Professor of Medicine and Director of the TCSCP at UCSF, and Dr. Yerem holds many titles and distinctions including: The Leone-Perkins Family Endowed Chair in Cardiology Director of the Translational Cardiac Stem Cell Program Co-Director of the Adult Cardiac Catheterization Laboratory Director of the Peripheral Interventional Cardiology Program Immediate Past President of the San Francisco Board of the American Heart Association Previously, Dr. Yerem was the Chief Medical Resident and Instructor of Medicine the Brigham and Women s Hospital, Harvard Medical School. Dr. Yerem received a B.S. in Biology/Biochemistry from Brandeis University and a M.D. from The Johns Hopkins School of Medicine. Dr. Kurosh Ameri, PH.D. Chief Scientist UCSF Dr. Kurosh is the Chief Scientist and Associate Director of the TCSCP at UCSF. He has been at UCSF since 2010. Previously, Dr. Kurosh was the Senior Postdoctoral Scholar at Stanford University where he received the Medical School Dean s Award. Prior to Stanford, he was the EU-Young Scientist at Ludwig-Maximilians University of Munich. Dr. Kurosh received a BSc with Honors in Molecular Biology from The University of Glasgow in Scotland. He also received a Ph.D. from the University of Sheffield and the Cancer Research UK, University of Oxford. He received advance training in Molecular Medicine/Cancer Biology at the Weatherall Institute of Molecular Medicine, University of Oxford. Dr. Vien Nguyen, PH.D. Research Scientist Dr. Nguyen joined the Translation Cardiac Stem Cell Program in 2016. He specializes in developmental neurosciences, specifically stroke/hypoxia-ischemia encephalopathy. Previously, Dr. Nguyen joined UCSF in 2006 as a research associate. Dr. Nguyen received a BSc in Physics from the College of William and Mary. He also received a Ph.D. from UCSF in Biomedical Sciences Program. 6
TCSCP Director s Bios (Continued) Name Michael Khanjyan Medical Student Bio Mr. Khanjyan joined the UCSF Translational Cardiac Stem Cell in 2016 to research on patient-derived cardiac stem cells. Mr. Khanjyan is a medical student at UCSF with an expected graduation date of 2018. He received his BSc in physiological sciences from UCLA. Raffi Samurkashian Biomedical Engineering Student Mr. Samurkashian joined the UCSF Transnational Cardiac stem cell Research Program in 2014 and designed our first generation 3D Bioprinter. Mr. Samurkashian is an undergraduate student in Biomedical Engineering at UC-Davis. Kevin Huynh Medical Student Mr. Huynh joined the UCSF Transnational Cardiac Stem cell Research Program in 2017 as an intern-researcher to work on stem cells and stroke therapy. Mr. Huynh is a 2nd year Medical Student at UCSF. He completed his undergraduate degree (Magna cum laude) at UCSD in Biochemistry and Cell Biology, and has a Master Degree in Biology from UCSD. Olivia Tandowsky Student Miss Tandowsky joined the Translational Cardiac Stem Cell Program in 2017. Miss Tandowsky is an incoming sophomore undergraduate student at UC Berkeley, majoring in cognitive science with an emphasis in neuroscience. She plans on attending Medical School after receiving her bachelor of arts in 2020. Leili Najmabadi Student Miss Najmabadi joined the Translational Cardiac Stem Cell Program in 2017. Miss Najmabadi is a sophomore at Tufts University and a Rwanda fellow. She plans on studying Community Health while being on the pre-med track. In college, she writes for TuftScope, the interdisciplinary journal of health, ethics, and policy. 7
UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research 8
UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research 9
Fundraising Goals: Two Year Target of $10M Five Year Target of $25M Near Term Goal: $10M Continued research at the TCSCP will allow us to develop and translate our breakthrough discoveries into novel clinical therapies to help millions of patients To achieve our goals of successful drug development, funds are needed to carry out detailed molecular biology, cell biology, pharmacology, medicinal chemistry, drug design, in-vitro assays, and in-vivo experimentations Raised: $3.7M Funds raised will support our continued research by enabling us to: Hire key personnel with specific expertise in their field Purchase necessary equipment to conduct our research Purchase the necessary supplies and samples to conduct our various modifying, testing and optimizing procedures to develop stem cell-derived drugs Please write your tax deductible check to: UCSF Foundation Include Yerem Yeghiazarians/B2041 on the memo line Send to: UCSF foundation Attn: Eileen Murphy PO Box 45339 San Francisco, CA 94145-0339 Tax ID Number: 94-2829914 10